Array reports updated Phase III OS data for triple combo mCRC therapy

Array BioPharma Inc. (NASDAQ:ARRY) reported updated data from the safety lead-in portion of the Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and

Read the full 274 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE